Introduction
============

Cancer biology has led to the development of parallel concepts that provide a general framework; among them are: hallmarks of cancer, cancer metabolic map and cancer heterogeneity. There are few attempts to integrate these concepts. In this review, we outline them and their compatibility, and we show that there is no one unique metabolic map of a heterogeneous cancer. This is often acknowledged and discussed in specialized articles on cancer cell metabolism, but not in reviews and textbook chapters on cancer.

Hallmarks of cancer
===================

Hallmarks of cancer have been proposed as general concepts of the common properties of cancer.^[@bib1]^ The first and the follow-up articles on the topic are most cited in the fundamental oncology literature.^[@bib1],\ [@bib2]^ The concept of hallmarks has been used with different meanings in different derived articles. It could apply to cancer in general or to the idealized 'cancer cell\' of the molecular biologists. The latter one often corresponds to our main research tool: cancer cell lines. However, cancer cell lines are poorly representative of cancer cells *in vivo*.^[@bib3]^ Moreover, the reasoning on cell lines explains why one of the first steps of tumorigenesis, that is, dedifferentiation^[@bib4]^ was not considered. The authors later pointed out that tumors are complex tissues, and emphasized the role of tumor microenvironment.^[@bib2]^ Nevertheless, in many articles, the ambiguity about the object to which the concept is applied leads to misconceptions.^[@bib4]^ Hallmarks are in fact properties of the cancer as a whole and of some of cancer cells sometimes.

Among the emerging hallmarks considered in 2011 was the reprogramming of energy metabolism.^[@bib2],\ [@bib5],\ [@bib6]^ However, reviews and textbooks generally continue to present an idealized picture of the 'cancer cell\' metabolism.^[@bib7]^

The cancer metabolism
=====================

Since Warburg\'s original discovery,^[@bib8]^ high levels of glycolysis and a low respiration rate, even in normoxic conditions, have been considered as a fundamental property and, sometimes, as a cause of cancer.

The 'Warburg effect\' consists in an enhancement of glucose metabolism through glycolysis, often coupled to an inhibition of mitochondrial pyruvate oxidation, resulting in elevated lactate production in the presence of oxygen. For non-cancer cells, this is the normal pattern of metabolism in hypoxic conditions.^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ In cancer cells, the Warburg effect can be coupled to an upregulation of cellular and mitochondrial glutamine uptake, which can, to some extent, compensate the reduced pyruvate availability at the mitochondrial level for adenosine triphosphate production and for biosynthesis (anaplerosis). It may also be coupled to an increased export to the cytosol of tricarboxylic acid cycle intermediates (cataplerosis) by which mitochondria feed pyruvate and citrate synthesis, to the activation of fatty acid metabolism, and to the synthesis of aminoacids and pentoses.^[@bib12],\ [@bib13]^ This metabolic reprogramming is of course wider than the effect initially described by Warburg^[@bib6]^ ([Figure 1](#fig1){ref-type="fig"}).

Metabolic reprogramming is mediated at the transcriptional and posttranscriptional level of metabolic enzymes and transporters. In particular, a significant part of the metabolic changes associated to the Warburg effect can be ascribed to hypoxia-inducible transcription factors (HIF-1 and HIF-2). These factors are normally activated in hypoxia because of a reduction in the natural degradation rate of their α subunits that requires the presence of O~2~. HIFs are further controlled positively by oncogenes (for example, MYC) and negatively by tumor-suppressor genes.^[@bib5],\ [@bib6],\ [@bib10],\ [@bib14]^ Adaptation to hypoxia, and notably HIF activation, further promotes invasion and metastasis, immune resistance by recruitment of Treg lymphocytes and tumor macrophages and so on.^[@bib10],\ [@bib15],\ [@bib16]^

This common phenotype of cancer cells metabolic transformation is considered to be essential for their growth and progression.^[@bib5]^ In cancer cell lines, it also promotes resistance to anoikis.^[@bib17]^ When predominant, the glycolytic activity demonstrated by high-lactate levels in tumors predicts the likelihood of tumor aggressiveness and metastasis in several cancer types.^[@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^

Dynamic heterogeneity of cancer
===============================

Although tumor heterogeneity has become a byword, our language, reasoning and investigations often assume homogeneous systems. As a result, a misleading tendency for molecular biologists, accustomed to work on homogenous populations of cancer cell lines, is to extrapolate their observations to *in vivo* tumors.^[@bib3]^ A same simplification entails the interpretation by many researchers of the concept of hallmarks of cancers and map of cancer metabolism, with an erroneous assumption of homogeneity. Common tools of cancer research, such as measurements on biopsies or 'omic studies\' on pieces of tumors (DNA sequencing, genes and protein expressions, metabolomics and so on), further imply the same assumptions. In fact, pathologists familiar with tissue sections have always known about tumor heterogeneity.

The concept of tumor heterogeneity encompasses transient and quasi-permanent situations. There are at least the following four aspects in this heterogeneity ([Figure 2](#fig2){ref-type="fig"}): Cell populations (stromal cells, different tumor clones and so on).Cell localization (for example, close or distant from other cells, from perfused blood vessels, from O~2~ and nutrient resources and so on).Timing in signal transduction from minutes for direct and posttranslational controls, to hours for transcriptional controls, to days and months for epigenetic mechanisms, and permanence for genetic effects.Patterns of metabolism and cell biology (for example, epithelial mesenchymal transition; *vide infra*).

For cell population heterogeneity, the coexistence of invading tumor cells and normal cells, the presence in the tumor mass of stromal cells such as cancer-associated fibroblasts, of macrophages, lymphocytes and endothelial cells are prime examples. This cellular heterogeneity varies much from one type of cancer to another. For instance, thyroid papillary and anaplastic carcinomas may contain as many associated cells as cancer cells (CAFs as cancer-associated fibroblasts in PTC, and TAM as tumor-associated macrophages in ATC), while follicular carcinomas are more homogeneous and are populated mostly by cancer cells. In papillary thyroid carcinomas, the proportion of cancer-associated cells correlates with malignity.^[@bib23],\ [@bib24]^

In the cancer cells population, clonal evolution gives rise to clones that progressively accumulate genetic mutations^[@bib25],\ [@bib26]^ and epigenetic alterations. Heterogeneity of different clones may favor cooperation for growth^[@bib27]^ and metastasis.^[@bib28]^ Also, even among the cancer cells themselves, only a minority may be responsible for cancer progression. In breast cancers, a comparison of cells and tumor duplication rates has shown that a majority of the cancer cells die, whereas only a minority of them drives cancer growth.^[@bib29],\ [@bib30]^ This may, but does not necessarily, reflect a Darwinian cell evolution.^[@bib31]^ Similarly, in normal tissues, cells may display somatic mosaicism.^[@bib32]^ Finally, even in a homogenous cell line in culture, stochastic state transitions give rise to phenotypic equilibrium in populations.^[@bib33]^

Concerning the different cell localizations, they depend on an evolving vascular development, perfusion abnormalities^[@bib34],\ [@bib35]^ and on tumor growth. Similar cells from normally oxygenated (normoxic) areas will, when distant from functional blood vessels capable of carrying red blood cells, progressively degenerate into slightly to deeply hypoxic areas. Shifts in cell behavior and protein patterns imposed by the environment, for example by lactate or H^+^ as signals,^[@bib36]^ may promote mechanisms of cell migration, amoeboid or collective,^[@bib37],\ [@bib38]^ angiogenesis and immunosuppression.^[@bib36],\ [@bib39]^ They may result from epigenetic, transcriptional, translational or posttranslational mechanisms, and be more or less reversible.^[@bib38],\ [@bib40],\ [@bib41]^ Thus, tumors have been described as evolving ecosystems.^[@bib42]^ Changes imposed by the microrenvironment may also exist permanently, even in genetically homogenous populations of unicellular organisms.^[@bib43]^ Permanent and transient switches are often objectivated by single cell RNA sequencing.^[@bib44]^ This intratumoral heterogeneity evolves through space and time.^[@bib45]^

Finally, the time issue cannot be dissociated from the concept of cycles. Cancer cells may for instance be in an hypoxic environment for only a transient period of time either because angiogenesis is developing in response to low pO~2~ and re-oxygenation will progressively occur, or because the highly immature tumor vasculature that was not functional is suddenly re-perfused because of an hemodynamic change (for example, red blood cells that were plugged in a poorly organized tumor capillary are suddenly re-mobilized).^[@bib46]^ These phenomena have been proposed to repeat themselves with different frequencies.^[@bib35]^ Importantly, these cycles of hypoxia/reoxygenation (more exactly, variations between deep and moderate hypoxia) have been shown to influence the phenotype of cancer cells but also endothelial cells.^[@bib47],\ [@bib48]^ The gene program induced by intermittent or cycling hypoxia is very different from that corresponding to continuous hypoxia. Of note, a transcriptomic signature derived from cycling hypoxia was recently documented to have a very efficient prognostic potential to discriminate between low- and high-risk breast cancer patients,^[@bib49]^ indicating that the capacity of tumor to adapt to heterogeneous conditions of oxygenation and perfusion could be linked to cancer aggressiveness.

Consequences of heterogeneity
=============================

Ignoring tumor heterogeneity has at least two consequences: (a) it may lead to erroneous interpretations of research and clinical data, and (b) it masks the complex network of cellular interactions that govern tumor behavior.

In the first case, increase in the global measurement of the content of one RNA or enzyme in some cells may mask the decrease of the same RNA or enzyme in other cells and conversely. Thus, one may find in global data of a set of cells evidence of activation of a reaction in opposite senses (lactate influx and efflux, coincrease of MCT4 and MCT8, of LDH A and LDH B and so on).^[@bib50]^ In one cell, this would constitute a futile cycle, which in a competitive environment could be suicidal. However, a coexpression of opposite enzymes whose activity is controlled posttrancriptionnally would provide the possibility of rapid switches. The metabolic profile of a cell has to make biological sense. As a typical example of possible misinterpretations, the heterogeneity of a renal carcinoma led to both good and bad prognosis signatures by sequencing different fragments of the same piece of tissue.^[@bib51]^

On the other hand, the coexistence of different types of cells and of similar cells with different metabolic phenotypes in response to different environments may be essential for tumor progression.^[@bib52]^ For example, there is a strong interrelation of cancer cells and TAMs in thyroid anaplastic carcinoma cells,^[@bib53]^ and CAFs in thyroid papillary carcinoma,^[@bib23],\ [@bib24]^ and of fibroblasts with breast and ovarian cancer cells and so on. In the latter cases, this association in desmoplasia has been shown to be a crucial element in cancer progression.^[@bib54]^ Breast cancer heterogeneity is a strong negative predictor of outcome, which suggested that Darwinian competition would be beneficial for the tumor.^[@bib55]^

Heterogeneity and metabolism
============================

Among cancer cells themselves, clonal evolution may lead to diversity and heterogeneity, and variations in location and time may further cause transient or permanent differences. Cancer cells are notoriously resourceful,^[@bib56]^ and may use this diversity. For instance, they can switch mitochondrial substrates from glucose to glutamine and conversely through transcriptional control.^[@bib13],\ [@bib57]^

Adaptability is especially relevant to cancer cell metabolism, with short-term and permanent adaptations. At the molecular level, the Warburg effect encompasses increased glucose metabolism to lactate (glycolysis) and to the pentose phosphate pathway. Anaplerosis and cataplerosis are not strictly linked to the Warburg effect. These metabolic changes involve: (a) activation and/or upregulation of glucose transporters, hexokinases and glycolytic enzymes (for example, PKM2), lactate dehydrogenases (LDH) and transporters of lactate (for example, MCT) and protons (for example, carbonic anhydrase IX); and (b) downregulation or inactivation by PDK2 of pyruvate dehydrogenase and so on. Fuel availability may itself determine the metabolic preference: cancer cells that produce lactate as long as glucose is available may recapture lactate when glucose is lacking, lactate being then reconverted in pyruvate to fuel the tricarboxylic acid cycle.^[@bib58]^

Adaptation to O~2~ availability can be rapid (minutes), involving direct and posttranslational regulations, or slow with chronic or delayed changes involving transcriptional, epigenetic and genetic mechanisms. Both types of responses can be evaluated with labeled glucose in culture and *in vivo*,^[@bib59]^ giving an integrated global picture. However, even for clonal cells, the relation between hypoxic and normoxic areas of a cancer depends on variations in blood flow, which may be rapid.^[@bib34],\ [@bib35],\ [@bib60]^ This can be tested *in vivo*, and, indeed, an increased O~2~ supply rapidly decreases glucose uptake in tumors.^[@bib61]^ The delayed or chronic type of cell adaptation to hypoxia is often demonstrated a posteriori by histology and molecular biology on tumors,^[@bib5],\ [@bib10],\ [@bib14],\ [@bib19],\ [@bib62]^ or on metastases.^[@bib63]^

Chronic regulations of metabolic heterogeneity can be studied directly *in vitro* in culture, and their consequences can be evaluated *in vivo*, notably on biopsies. In general, the O~2~ and glucose supplies of a given tumor are co-modulated by the blood supply of the tumor, to the exception of blood vessels that are perfused by plasma only but do not carry red blood cells. The transport capacity of blood vessels is clearly reduced by the chaotic state of the tumor microvasculature.^[@bib35],\ [@bib60]^ However, the cellular consequences of a reduced blood supply are very different when considering O~2~ and glucose availability. Arterial 5% O~2~ corresponds to 10 μmol/l, whereas 900 mg/l of glucose corresponds to 5000 μmol/l. Oxygen is poorly soluble in water, hence in the plasma, whereas glucose is. Thus, oxygen is a more limiting resource when compared with glucose. Consequently, cells distant from the well-perfused capillaries will be hypoxic but could still be supplied in glucose. The already low pO~2~ near capillaries decreases with distance and thus often with the size of the tumor,^[@bib64]^ with sometimes more than 60% of the cells being hypoxic in established tumors.^[@bib65]^ The effects of low O~2~ and the consequent limitation of oxidative phosphorylation prevent the growth of breast cancer cells, but less so of cancer-associated fibroblasts.^[@bib66]^

The coexistence in the same tumor of hypoxic and normoxic cells has been modeled *in vitro*. It leads to a symbiosis between the two populations of largely specialized cells.^[@bib52]^ In 3D structures *in vitro*, and in experimental tumors *in vivo*, the normoxic cells are at the periphery and the hypoxic cells are in the center of a spheroid. This suggests a metabolic map for each type of cell.^[@bib67]^ In these maps, hypoxic cells produce lactate from glucose (anaerobic glycolysis) and normoxic cells take it up and oxidize it ([Figure 3](#fig3){ref-type="fig"}). Similar metabolic relationships can also exist between cancer and stromal cells. Metabolic commensalism has been described with cancer cells releasing reactive oxygen species that promote a glycolytic metabolic pathway in CAFs, that in turn provides the oxidative cancer cells with lactate and ketone bodies.^[@bib20],\ [@bib68],\ [@bib69]^ CAFs have also been shown to be major contributors to extracellular acidification, promoting the epithelial mesenchymal transition of the tumor cells.^[@bib70]^

There would therefore exist at least two different archetype metabolic maps for a given cancer, and there might also be intermediates.^[@bib28],\ [@bib36]^ The metabolic maps indicate global enzymatic activities, which reflect effects on their activity and on the expression of different isoforms. The former are rapid and will only be demonstrated grossly with labeled substrates.^[@bib59]^ The latter results from controls at translational, transcriptional, epigenetic and even genetic levels.^[@bib10]^

The different components of cancer metabolism (glucose, glutamine, lipid and lactate metabolism, pyruvate carboxylation, anaplerosis/cataplerosis and so on) may not always be tightly linked, for example, the mitochondrial use of glutamine may occur independently of O~2~ consumption.^[@bib57],\ [@bib71],\ [@bib72]^ However, crosstalks may exist. For example, intracellular lactate promotes glutamine uptake and metabolism in oxidative cancer cells^[@bib73]^ and conversely, anaplerosis, the conversion of pyruvate to oxaloacetate by pyruvate carboxylase, allows glucose to fuel glutamate synthesis.^[@bib74]^ Potential contributions of non-glucose nutrients in well-perfused tumor areas should also be considered^[@bib59]^ together with the influence of acidosis that was recently shown to shift tumor metabolism from glucose to glutamine and fatty acid metabolism.^[@bib75]^ In fact the great metabolic flexibility of cancer cells *in vivo* and *in vitro* multiplies the number of possible coexisting metabolic maps.^[@bib76]^

The possibility of intermediate states between metabolic phenotypes is doubtful as they would represent bidirectional pathways, that is, wasteful futile cycles. It is therefore probable that all or none controls (for example, by positive feedbacks) would impose switches rather than gradual metabolic states. Even if it is not mentioned, published histochemical studies indeed rather suggest clean demarcations between tumor aerobic and anaerobic areas rather than progressive transitions.^[@bib10],\ [@bib63]^

The validity of the concepts of hypoxic and normoxic areas in *in vivo* tumors is supported by differential uptakes of glucose in hypoxic and vascularized regions of the tumors,^[@bib59],\ [@bib77]^ by the use of markers of hypoxia such as pimonidazole and carbonic anhydrase IX staining as well as ^18^Fluoromisonidazole (^18^F-MISO), and by direct pO~2~ measurements and electron paramagnetic resonance oxymetry.^[@bib36]^ Dynamic contrast-enhanced MRI combined with ^13^C glucose infusion suggests that the relatively stable perfusion state of lung tumors is a major contributor of metabolic variability.^[@bib59]^ In fact, there is a correlation between this duality and tumor aggressiveness in urothelial bladder cancers.^[@bib78]^ Of course, the situation may vary from one tumor type to another.

Conclusions
===========

The dynamic heterogeneity of metabolic phenotypes in tumors and metastases has consequences. On the conceptual point of view, the unique cancer metabolic map gives an erroneous oversimplified static description of the heterogeneous, versatile, adaptable cancer metabolism. From the diagnostic standpoint, the metabolic pattern of a cancer biopsy cannot be considered as representative of the whole tumor. With regard to therapeutics, heterogeneity raises problems.^[@bib45]^ Transient and location-dependent phenotypes may not be considered as suitable targets, unless largely predominant or attacked jointly.^[@bib36]^ More interesting features may be the chronic ones, such as proliferation targeted by recurrent chemo and radiotherapy.
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![Simplified scheme of 'the metabolic map of cancer cell\'. The classical normal cell metabolism in the presence of O~2~, from glucose to pyruvate, mitochondrial acetyl-CoA, and through the Krebs cycle to CO~2~: black lines. The glycolytic Warburg pathway, from glucose to pyruvate and lactate: red lines. The pathways, from glutamine, acetate, and fatty acids to aminoacids, nucleotides and fat: green lines. The Krebs cycle: yellow lines. accos, acetylcoA synthase; aldo, aldolase; Atp cl, adenosine triphosphate citrate lyase; eno, enolase; FaCoA, fatty acyl-CoA; ffk, phosphofructokinase; gapdh, glyceraldehyde phosphate dehydrogenase; glnase, glutaminase; glut1, glucokinase; glutdh, glutamic acid dehydrogenase; gpi, glucose phosphate isomerase; hk, hexokinase; ldh, lactate dehydrogenase; mct, monocarboxylic acid transporter; me, malic enzyme; oxalo, oxaloacetate; pc, pyruvate carboxylase; pdh, pyruvate dehydrogenase; pdhk, pyruvate dehydrogenase kinase; pck2, pyruvate carboxykinase; pgk, phosphoglycerate kinase; pkm2, pyruvate kinase m2; tpi, triose phosphate isomerase.](onc2016411f1){#fig1}
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![The two states metabolic map. Expression and Biology CA, carbonic anhydrase; CAF, cancer-associated fibroblasts; LDH, lactate dehydrogenase; HIF, hypoxia inducible factor; Lox, lysyl oxidase; MCT, monocarboxylic transporter; PDH, pyruvate dehydrogenase; PDHK, pyruvate dehydrogenase kinase; PKM2, pyruvate kinase M2; TOMM20, translocase of outer mitochondrial membrane 20.](onc2016411f3){#fig3}
